Accessibility Menu
 
Precision BioSciences logo

Precision BioSciences

(NASDAQ) DTIL

Current Price$6.05
Market Cap$148.85M
Since IPO (2019)-99%
5 Year-98%
1 Year+33%
1 Month+47%

Precision BioSciences Financials at a Glance

Market Cap

$148.85M

Revenue (TTM)

$34.26M

Net Income (TTM)

$46.61M

EPS (TTM)

$-5.18

P/E Ratio

-1.16

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Price

$6.05

Volume

534,176

Open

$6.51

Previous Close

$6.02

Daily Range

$5.78 - $6.51

52-Week Range

$3.53 - $8.82

DTIL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Precision BioSciences

Industry

Biotechnology

Employees

68

CEO

Michael Amoroso, EMBA

Headquarters

Durham, NC 27701, US

DTIL Financials

Key Financial Metrics (TTM)

Gross Margin

94%

Operating Margin

-2%

Net Income Margin

-1%

Return on Equity

-63%

Return on Capital

-36%

Return on Assets

-30%

Earnings Yield

-86.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$148.85M

Shares Outstanding

24.73M

Volume

534.18K

Short Interest

0.00%

Avg. Volume

277.80K

Financials (TTM)

Gross Profit

$31.51M

Operating Income

$52.15M

EBITDA

$49.40M

Operating Cash Flow

$65.84M

Capital Expenditure

$85.00K

Free Cash Flow

$65.93M

Cash & ST Invst.

$115.58M

Total Debt

$28.81M

Precision BioSciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$34.20M

+5261.1%

Gross Profit

$33.53M

+5154.9%

Gross Margin

98.02%

N/A

Market Cap

$148.85M

N/A

Market Cap/Employee

$1.38M

N/A

Employees

108

N/A

Net Income

$19.25M

+208.5%

EBITDA

$13.19M

+179.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$86.78M

+54.2%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$27.30M

-5.0%

Short Term Debt

$1.51M

+14.2%

Return on Assets

-30.18%

N/A

Return on Invested Capital

-35.84%

N/A

Free Cash Flow

$11.28M

+39.9%

Operating Cash Flow

$11.25M

+39.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARTVArtiva Biotherapeutics, Inc.
$5.01-2.91%
RPTXRepare Therapeutics Inc.
$2.65+0.00%
ALXOALX Oncology Holdings Inc.
$2.04+0.00%
CNTBConnect Biopharma Holdings Limited
$3.45-6.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About DTIL

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.